Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
niraparib + brivanib
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of niraparib, an FDA-approved PARP (poly ADP-ribose polymerase) inhibitor, and brivanib, an anti-angiogenic agent that targets FGFR1 (fibroblast growth factor receptor 1). This combination has shown synergistic antitumor effects, particularly in ovarian cancer cells with BRCA mutations, by enhancing programmed cell death mechanisms including apoptosis and necroptosis. The combination is being investigated for the treatment of various cancers including ovarian cancer and cervical cancer.
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on niraparib + brivanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on niraparib + brivanib.